Amikacin

The Amikacin test measures the concentration of amikacin in the blood. Amikacin is an aminoglycoside antibiotic used to treat selected serious bacterial infections, particularly infections caused by organisms resistant to other antibiotics. It may be used for severe hospital-acquired infections, bloodstream infections, complicated urinary infections, bone and joint infections, abdominal infections and certain mycobacterial infections when clinically appropriate.

Amikacin can be effective against difficult-to-treat bacteria, but the difference between an effective exposure and a potentially harmful exposure may be relatively narrow. Therapeutic drug monitoring helps doctors individualise treatment by evaluating whether the blood concentration is appropriate for the prescribed dosing method, infection and patient. Correct timing of sample collection is essential because amikacin levels rise after a dose and then fall as the kidneys remove the medicine.

Benefits of the Test

• Measures the concentration of amikacin circulating in the blood.
• Supports individualised antibiotic dosing.
• Helps assess whether drug exposure is likely to be adequate for treatment.
• Reduces the risk of excessive accumulation and toxicity.
• Supports safer treatment in patients with reduced or changing kidney function.
• Helps doctors evaluate peak, trough or other protocol-specific concentrations.

Why Doctors Recommend This Test

Doctors may recommend amikacin monitoring when the medicine is used for a serious infection, when treatment is expected to continue for several days, or when the patient has a higher risk of drug accumulation. Risk factors include impaired kidney function, older age, critical illness, dehydration, major changes in fluid balance, burns and treatment with other medicines that can affect the kidneys or hearing.

A peak level may be measured to evaluate whether the drug concentration after administration is sufficient for antibacterial activity. A trough level is collected shortly before the next dose to determine whether the medicine has fallen to a suitably low concentration and is not accumulating excessively. Some treatment protocols use a single timed level after an extended-interval dose rather than conventional peak and trough testing. The requested collection schedule should therefore be confirmed with the treating team.

High or persistent concentrations can increase the risk of nephrotoxicity, which affects the kidneys, and ototoxicity, which can damage hearing or balance. Possible warning symptoms include reduced urine output, swelling, unusual weakness, ringing in the ears, hearing changes, dizziness or problems with balance. These symptoms require prompt medical review and should not be assessed using the blood level alone.

Preparation Before Test

Fasting is generally not required. The patient or healthcare team must provide the exact time of the most recent amikacin dose, dose amount, method of administration and sample-collection time. Incorrect timing can make an otherwise accurate laboratory measurement clinically misleading.

Do not delay, skip or change an amikacin dose unless instructed by the treating doctor. Inform the medical team about kidney disease, hearing problems, dehydration and all current medicines. Blood is collected at the specific time requested by the doctor, such as shortly before the next dose for a trough level or at a defined interval after administration for a peak or random level.

Normal Reporting Time

Amikacin measurement is a specialized therapeutic drug-monitoring assay. Results are generally available within a few working days, although timing may vary with the collection centre, testing schedule, sample transportation and whether repeat analysis is required. Because dosing decisions may be time-sensitive, the treating team should confirm availability and the expected reporting time before collection.

Who Should Take This Test?

• Patients receiving amikacin for a serious bacterial infection.
• People undergoing prolonged or high-intensity aminoglycoside treatment.
• Patients with impaired, unstable or rapidly changing kidney function.
• Older adults, critically ill patients and those with major fluid-balance changes.
• Patients receiving other medicines that may damage the kidneys or hearing.
• Anyone whose doctor needs to assess amikacin exposure or investigate possible toxicity.

Detailed Information

Amikacin is eliminated mainly through the kidneys. Reduced kidney filtration can slow its removal, allowing the drug to accumulate between doses. Doctors therefore interpret the level with serum creatinine, estimated glomerular filtration rate, urine output, age, body weight, infection severity and dosing schedule. Kidney function is usually monitored repeatedly during treatment.

There is no single target concentration suitable for every patient. Target values depend on whether conventional multiple-daily dosing or extended-interval dosing is used, whether the sample is a peak, trough or random measurement, the infecting organism and the site of infection. Reference or target intervals may also differ between clinical protocols. The result must be interpreted by the treating clinician or clinical pharmacist rather than compared with a general range without context.

An unexpectedly high result may lead the treating team to delay a dose, extend the interval, reduce the dose or reassess kidney function. A low concentration may prompt review of the dose, collection timing, administration record, bacterial susceptibility and clinical response. Changes must only be made by the responsible healthcare professional.

Therapeutic drug monitoring does not replace microbiological culture and antibiotic-susceptibility testing. Culture results help determine whether the infection-causing organism is susceptible to amikacin, while the blood-level test evaluates drug exposure. Used together with clinical monitoring and kidney assessments, these investigations support safer and more effective antibiotic treatment.